CareDx, Inc. (FRA:1K9)
Germany · Delayed Price · Currency is EUR | Market Cap | 979.14M +11.7% |
| Revenue (ttm) | 358.04M +19.2% |
| Net Income | -7.10M |
| EPS | -0.14 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 24.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 18.70 |
| Previous Close | 19.30 |
| Day's Range | 18.70 - 18.70 |
| 52-Week Range | 9.83 - 19.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About CareDx
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about dist... [Read more]
News
CareDx denied request to Supreme Court to revive Natera award
A writ of certiorari was denied by the U.S. Supreme Court in the case of CareDx (CDNA) v. Natera (NTRA), meaning that the Court has declined to hear the appeal,…
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx announces dismissal of 2021 Qui Tam Suit
CareDx (CDNA) announced the dismissal of a qui tam action filed against the Company. On April 23, 2026, the United States District Court for the Eastern District of New York…
CareDx Announces Dismissal of 2021 Qui Tam Suit
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinica...
CareDx price target raised to $28 from $26 at BTIG
BTIG raised the firm’s price target on CareDx (CDNA) to $28 from $26 and keeps a Buy rating on the shares. The company has announced many positive updates on its…
CareDx files automatic mixed securities shelf
17:08 EDT CareDx (CDNA) files automatic mixed securities shelf
CareDx to acquire Naveris for $160M up-front, $100M in revenue milestones
The Transplant Company announced it has entered into a definitive agreement to acquire Naveris. The transaction is an extension of CareDx’s (CDNA) strategy to focus on its U.S. Precision Medicine…
CareDx raises FY26 revenue view to $447M-$465M from $420M-$444M
Consensus $437.43M. The Company now expects full year 2026 adjusted EBITDA to be in the range of $43 million to $57 million.
CareDx Earnings Call Transcript: Q1 2026
Q1 revenue grew 39% year-over-year, driven by strong testing and digital solutions growth. The company divested its lab products business and acquired Navoris, expanding into viral-mediated cancer MRD with a differentiated, Medicare-covered platform. 2026 guidance was raised, with no Navoris contribution included.
CareDx Earnings release: Q1 2026
CareDx released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
CareDx Quarterly report: Q1 2026
CareDx has published its Q1 2026 quarterly earnings report on April 28, 2026.
CareDx Slides: Q1 2026
CareDx has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
CareDx reports Q1 EPS 34c, consensus 13c
Reports Q1 revenue $118M, consensus $104.45M. “Our team delivered another quarter of record growth, driven by continued momentum in our Precision Medicine Testing Services and Patient and Digital Solu...
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx Announces First Quarter 2026 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx Proxy statement: Proxy filing
CareDx filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
CareDx Proxy statement: Proxy filing
CareDx filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual Meeting
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
CareDx introduces AlloSeq Nano at EFI 2026
CareDx (CDNA) introduced AlloSeq Nano, a nanopore-based HLA and ABO blood type genotyping solution, at the European Federation for Immunogenetics Conference 2026. AlloSeq Nano is an innovation develop...
CareDx expects EuroBio agreement to close by end of Q3
CareDx (CDNA) announced on April 15 that it entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific, which is expected to close by the end…
CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...
Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product division
EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX's TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx's ‘lab products' portfolio creates new opportunities for growth and innovation i...
CareDx up 20% at $21 after Q1 pre-announcement, Lab Products divestment
16:37 EDT CareDx (CDNA) up 20% at $21 after Q1 pre-announcement, Lab Products divestment
CareDx to divest Lab Products unit to EuroBio for $170M cash consideration
CareDx (CDNA) announced that it has entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific for cash consideration of $170M. The transaction has been approved…